Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
|
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 50 条
  • [1] Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
    Suzuki, Motoyuki
    Takenaka, Yukinori
    Kishikawa, Toshihiro
    Yamamoto, Yoshifumi
    Hanamoto, Atsushi
    Tomiyama, Yoichiro
    Fukusumi, Takahito
    Michiba, Takahiro
    Takemoto, Norihiko
    Nakahara, Susumu
    Inohara, Hidenori
    ANTICANCER RESEARCH, 2021, 41 (04) : 2045 - 2051
  • [2] Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
    Posch, Doris
    Fuchs, Hannah
    Kornek, Gabriela
    Grah, Anja
    Pammer, Johannes
    Aretin, Marie-Bernadette
    Fuereder, Thorsten
    SCIENTIFIC REPORTS, 2016, 6
  • [3] Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
    Doris Posch
    Hannah Fuchs
    Gabriela Kornek
    Anja Grah
    Johannes Pammer
    Marie-Bernadette Aretin
    Thorsten Fuereder
    Scientific Reports, 6
  • [4] Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
    Hannah Fuchs
    Johannes Pammer
    Christoph Minichsdorfer
    Doris Posch
    Gabriela Kornek
    Marie-Bernadette Aretin
    Thorsten Fuereder
    Medical Oncology, 2018, 35
  • [5] Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
    Fuchs, Hannah
    Pammer, Johannes
    Minichsdorfer, Christoph
    Posch, Doris
    Kornek, Gabriela
    Aretin, Marie-Bernadette
    Fuereder, Thorsten
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [6] First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
    Falco, Agustin
    Leiva, Mariano
    Blanco, Albano
    Cefarelli, Guido
    Rodriguez, Andres
    Melo, Juan
    Cayol, Federico
    Rizzo, Manglio Miguel
    Sola, Alejandro
    Rodriguez Montani, Hernan
    Chacon, Matias
    Enrico, Diego
    Waisberg, Federico
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (02): : 147 - 158
  • [7] Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
    Hannouf, Malek B.
    Sehgal, Chander
    Cao, Jeffrey Q.
    Mocanu, Joseph D.
    Winquist, Eric
    Zaric, Gregory S.
    PLOS ONE, 2012, 7 (06):
  • [8] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
  • [9] The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
    Tejani, Mohamedtaki A.
    Cohen, Roger B.
    Mehra, Ranee
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 173 - 185
  • [10] Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
    Klinghammer, Konrad
    Lorini, Luigi
    Nevens, Daan
    Simon, Christian
    Machiels, Jean-Pascal
    Bossi, Paolo
    FRONTIERS IN ONCOLOGY, 2022, 12
12345